Is the t(11;14) translocation a stronger predictor of progression to overt multiple myeloma than the size of a solitary plasmacytoma?

t(11;14) is NOT a stronger predictor of progression to myeloma than plasmacytoma size

The size and characteristics of the plasmacytoma, along with bone marrow involvement, remain the primary determinants of progression risk in solitary plasmacytoma, while t(11;14) is a cytogenetic marker relevant to established multiple myeloma prognosis—not to predicting progression from solitary plasmacytoma.

Key Distinction in Disease Context

The critical issue here is that you're asking about two different clinical scenarios:

• Solitary plasmacytoma is a localized disease where progression risk is determined by tumor burden factors
• t(11;14) is a cytogenetic abnormality studied in the context of established multiple myeloma, not solitary plasmacytoma

What Actually Predicts Progression from Solitary Plasmacytoma

According to the European expert panel guidelines, the primary risk factors for progression from solitary plasmacytoma to overt myeloma are 1:

• Presence of minimal bone marrow plasmacytosis (even low-level monoclonal plasma cell infiltration indicates high risk of early progression)
• Type of plasmacytoma: Solitary bone plasmacytoma (SBP) has ~50% progression risk at 10 years versus extramedullary plasmacytoma (EMP) at ~30%
• Tumor size and extent on imaging (whole body PET-CT or MRI to exclude additional lesions)

The guidelines make no mention of t(11;14) testing in the solitary plasmacytoma setting 1.

Why t(11;14) is Not the Answer Here

t(11;14) is studied as a prognostic marker in established multiple myeloma, not as a predictor of progression from solitary disease:

• In multiple myeloma, t(11;14) is now recognized as conferring intermediate to poor prognosis in the novel agent era 2, 3, 4
• The 2025 IMS/IMWG consensus on high-risk myeloma does not include t(11;14) alone as a high-risk marker 5
• Studies examining t(11;14) focus on patients with newly diagnosed multiple myeloma, not solitary plasmacytoma 2, 6, 3

Clinical Algorithm for Solitary Plasmacytoma Risk Assessment

When evaluating progression risk in solitary plasmacytoma, prioritize:

1. Bone marrow biopsy: Any detectable monoclonal plasma cells = high risk
2. Imaging: PET-CT or whole-body MRI to confirm true solitary nature
3. Type: SBP (70% of cases) has higher progression risk than EMP
4. Serum markers: Persistent M-protein after radiation suggests residual disease

Cytogenetic testing including t(11;14) is not part of standard solitary plasmacytoma workup and would only become relevant if/when the patient progresses to multiple myeloma.

Common Pitfall to Avoid

Do not conflate cytogenetic risk stratification used in multiple myeloma with risk assessment for solitary plasmacytoma progression. These are distinct clinical entities with different prognostic frameworks. The presence of bone marrow involvement—even minimal—is far more predictive of progression than any cytogenetic marker that might be found if you were to test for it.